Jyseleca tablets 100 mg for rheumatoid arthritis and ulcerative colitis (filgotinib maleate)

Are Jyseleca tablets 100 mg effective for rheumatoid arthritis and ulcerative colitis (filgotinib maleate)?

Managing rheumatoid arthritis or ulcerative colitis can be challenging, especially when conventional therapies fail to provide adequate relief. Jyseleca tablets with filgotinib maleate offer an effective, targeted solution by inhibiting the Janus Kinase enzyme, which plays a key role in inflammation and pain expression.

Jyseleca is designed for patients who have not responded well to traditional treatments. This advanced therapy is proven to reduce inflammation, alleviate pain, and improve mobility in those suffering from rheumatoid arthritis and ulcerative colitis.

Key Benefits of Jyseleca Tablets

• Effective for Rheumatoid Arthritis – Helps prevent structural joint damage and improves physical function.
• Proven Treatment for Ulcerative Colitis – Reduces flare-ups and supports long-term maintenance therapy.
• Fast Symptom Relief – Clinical trials indicate significant improvement within 12 weeks.
• Oral Convenience – Taken as a simple daily tablet, eliminating the need for injections.
• Clinically Tested and Approved – Supported by extensive research, including the FINCH 2 Randomized Clinical Trial published in July 2019, where up to 66% of patients showed clinical response.

How Jyseleca Works

Jyseleca filgotinib tablets target the Janus Kinase (JAK) enzyme, which regulates inflammatory responses. By inhibiting this enzyme, it reduces inflammation, swelling, and pain, making it an ideal choice for those experiencing inadequate relief from standard treatments.

Jyseleca is recommended for adults with:

• Moderate to severe rheumatoid arthritis that has not responded to conventional disease-modifying antirheumatic drugs (DMARDs).
• Moderate to severe ulcerative colitis, particularly for those who have failed previous treatments.

Proven Effectiveness

Filgotinib maleate has been extensively studied and received regulatory approval in Japan in 2020. Clinical trials, such as the FINCH 2 study by Genovese M. C., Kalunian K., et al. (July 2019), titled “Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial”, published in JAMA, involved 448 patients with inadequate response or intolerance to one or more biologic disease-modifying antirheumatic drugs. The study found that clinical response was achieved at week 12 in up to 66.0% of patients using filgotinib tablets.

If you suffer from persistent joint pain or debilitating digestive symptoms, Jyseleca tablets for rheumatoid arthritis and ulcerative colitis may provide the relief you need. Speak to your healthcare provider about this innovative treatment and start your journey toward a more comfortable, active life.

Package details: 14 tablets

Dosage and administration:

• Rheumatoid arthritis: adults should take 2 tablets (200 mg of filgotinib) at a time, once a day. Your doctor may decrease the dosage up to 1 tablet (100 mg) at a time, once a day, according to your condition.
• Ulcerative colitis: adults should take 2 tablets (200 mg of filgotinib) at a time, once a day. For maintenance therapy, your doctor may decrease the dosage up to 1 tablet (100 mg) at a time, once a day, according to your conditions.

Active components: filgotinib maleate

Therapeutic effect: treating rheumatoid arthritis with inadequate response to conventional therapies (including prevention of structural joint damage); treating moderate to severe ulcerative colitis (in the case with inadequate response to conventional therapies) and as its maintenance therapy.

Contraindications and precautions: Store in a dry cool place, out of reach of children. Do not use for pregnant or breastfeeding women. Do not use for patients with infections (pneumonia, sepsis, viral infection, etc.), active tuberculosis, renal dysfunction, liver dysfunction, decreased neutrophils, decreased lymphocyte, decreased hemoglobin, hepatitis B or a history of herpes zoster. If you have a childbearing potential, use birth control to avoid pregnancy while using this medicine and for a certain period after the completion of the therapy with this medicine. This medicine may cause impaired spermatogenesis and reduced fertility in men. Patient should routinely undergo laboratory tests such as chest X-ray while using this medicine in order to monitor for tuberculosis infection. This medicine may cause decreased neutrophils, decreased lymphocyte, decreased hemoglobin level or abnormal lipid level. Patient should routinely undergo blood test, including before treatment initiation. Patient should not receive live vaccines (such as BCG, measles, rubella, measles-rubella (MR), chicken pox and mumps vaccines) while using this medicine. Do not expose to sunlight or heat. If allergic symptoms occur, discontinue use.